David Toung
Stock Analyst at Argus Research
(4.63)
# 881
Out of 5,044 analysts
344
Total ratings
65.1%
Success rate
9.4%
Average return
Main Sectors:
Stocks Rated by David Toung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Rated: Buy | $200 → $330 | $301.79 | +9.35% | 12 | Sep 16, 2026 | |
| ELV Elevance Health | Reiterated: Hold | n/a | $412.70 | - | 6 | Aug 20, 2026 | |
| HCA HCA Healthcare | Rated: Buy | $500 | $451.09 | +10.84% | 5 | Aug 7, 2026 | |
| PFE Pfizer | Reiterated: Buy | n/a | $28.28 | - | 13 | Aug 5, 2026 | |
| BSX Boston Scientific | Downgraded: Hold | n/a | $42.73 | - | 11 | Jul 30, 2026 | |
| DGX Quest Diagnostics | Reiterated: Buy | $175 → $260 | $230.97 | +12.57% | 3 | Jul 28, 2026 | |
| JNJ Johnson & Johnson | Rated: Buy | $210 → $300 | $261.44 | +14.75% | 14 | Jul 28, 2026 | |
| DHR Danaher | Rated: Buy | $230 | $219.81 | +4.64% | 6 | Jul 23, 2026 | |
| UNH UnitedHealth Group | Reiterated: Buy | $400 → $470 | $379.30 | +23.91% | 15 | Jul 17, 2026 | |
| SYK Stryker | Rated: Buy | $450 → $370 | $277.33 | +33.42% | 12 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $25 | $13.44 | +86.01% | 7 | Jun 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $310 | $312.15 | -0.69% | 3 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $259.88 | - | 5 | May 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $85.21 | - | 2 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $610 → $560 | $658.02 | -14.90% | 10 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $115 | $88.48 | +29.97% | 18 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $290 → $180 | $183.75 | -2.04% | 16 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $280 → $400 | $323.85 | +23.51% | 19 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $110 → $95 | $65.74 | +44.51% | 3 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $87.29 | - | 3 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $431.87 | - | 21 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $65 → $68 | $72.46 | -6.16% | 10 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $570 → $775 | $938.84 | n/a | 15 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $150 | $99.60 | n/a | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $5.77 | n/a | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $962.56 | n/a | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $450 → $520 | $423.96 | n/a | 8 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $150 | $89.14 | n/a | 15 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $665 → $770 | $1,179.27 | n/a | 9 | Feb 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $265 → $300 | $414.87 | n/a | 5 | Nov 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $115 → $125 | $145.60 | n/a | 10 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $75 | $151.17 | n/a | 11 | Jan 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $59.12 | n/a | 6 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $115 → $140 | $276.47 | n/a | 14 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $143.75 | n/a | 2 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $237.57 | n/a | 10 | Aug 27, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $225.71 | n/a | 1 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $19 | $5.09 | n/a | 3 | Oct 21, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $24.35 | n/a | 3 | Aug 15, 2016 |
Charles River Laboratories International
Sep 16, 2026
Rated: Buy
Price Target: $200 → $330
Current: $301.79
Upside: +9.35%
Elevance Health
Aug 20, 2026
Reiterated: Hold
Price Target: n/a
Current: $412.70
Upside: -
HCA Healthcare
Aug 7, 2026
Rated: Buy
Price Target: $500
Current: $451.09
Upside: +10.84%
Pfizer
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $28.28
Upside: -
Boston Scientific
Jul 30, 2026
Downgraded: Hold
Price Target: n/a
Current: $42.73
Upside: -
Quest Diagnostics
Jul 28, 2026
Reiterated: Buy
Price Target: $175 → $260
Current: $230.97
Upside: +12.57%
Johnson & Johnson
Jul 28, 2026
Rated: Buy
Price Target: $210 → $300
Current: $261.44
Upside: +14.75%
Danaher
Jul 23, 2026
Rated: Buy
Price Target: $230
Current: $219.81
Upside: +4.64%
UnitedHealth Group
Jul 17, 2026
Reiterated: Buy
Price Target: $400 → $470
Current: $379.30
Upside: +23.91%
Stryker
Jul 9, 2026
Rated: Buy
Price Target: $450 → $370
Current: $277.33
Upside: +33.42%
Jun 17, 2026
Upgraded: Buy
Price Target: $25
Current: $13.44
Upside: +86.01%
Jun 2, 2026
Reiterated: Buy
Price Target: $310
Current: $312.15
Upside: -0.69%
May 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $259.88
Upside: -
May 21, 2026
Reiterated: Buy
Price Target: n/a
Current: $85.21
Upside: -
Apr 30, 2026
Reiterated: Buy
Price Target: $610 → $560
Current: $658.02
Upside: -14.90%
Apr 6, 2026
Reiterated: Buy
Price Target: $115
Current: $88.48
Upside: +29.97%
Mar 20, 2026
Rated: Buy
Price Target: $290 → $180
Current: $183.75
Upside: -2.04%
Mar 17, 2026
Reiterated: Buy
Price Target: $280 → $400
Current: $323.85
Upside: +23.51%
Mar 3, 2026
Rated: Buy
Price Target: $110 → $95
Current: $65.74
Upside: +44.51%
Dec 12, 2025
Reiterated: Buy
Price Target: n/a
Current: $87.29
Upside: -
Dec 8, 2025
Reiterated: Hold
Price Target: n/a
Current: $431.87
Upside: -
Nov 20, 2025
Rated: Buy
Price Target: $65 → $68
Current: $72.46
Upside: -6.16%
Aug 20, 2025
Rated: Buy
Price Target: $570 → $775
Current: $938.84
Upside: n/a
Apr 21, 2025
Reiterated: Buy
Price Target: $150
Current: $99.60
Upside: n/a
Mar 26, 2025
Reiterated: Hold
Price Target: n/a
Current: $5.77
Upside: n/a
Aug 15, 2024
Rated: Buy
Price Target: n/a
Current: $962.56
Upside: n/a
Jul 23, 2024
Reiterated: Buy
Price Target: $450 → $520
Current: $423.96
Upside: n/a
May 20, 2024
Upgraded: Buy
Price Target: $150
Current: $89.14
Upside: n/a
Feb 7, 2024
Reiterated: Buy
Price Target: $665 → $770
Current: $1,179.27
Upside: n/a
Nov 6, 2023
Reiterated: Buy
Price Target: $265 → $300
Current: $414.87
Upside: n/a
Jun 6, 2023
Reiterated: Buy
Price Target: $115 → $125
Current: $145.60
Upside: n/a
Jan 28, 2022
Upgraded: Buy
Price Target: $75
Current: $151.17
Upside: n/a
Nov 1, 2021
Downgraded: Hold
Price Target: n/a
Current: $59.12
Upside: n/a
Aug 5, 2021
Reiterated: Buy
Price Target: $115 → $140
Current: $276.47
Upside: n/a
Mar 10, 2021
Downgraded: Hold
Price Target: n/a
Current: $143.75
Upside: n/a
Aug 27, 2019
Downgraded: Hold
Price Target: n/a
Current: $237.57
Upside: n/a
Feb 16, 2018
Downgraded: Hold
Price Target: n/a
Current: $225.71
Upside: n/a
Oct 21, 2016
Reiterated: Buy
Price Target: $17 → $19
Current: $5.09
Upside: n/a
Aug 15, 2016
Reiterated: Hold
Price Target: n/a
Current: $24.35
Upside: n/a